研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

指乳头状腺癌患者的流行病学、生存率和随后发生原发性恶性肿瘤的风险:对监测、流行病学和最终结果 (SEER) 计划中的 213 名患者进行的回顾性研究。

Epidemiology, survival, and risk of subsequent primary malignancies in patients with digital papillary adenocarcinoma: a retrospective study of 213 patients in the Surveillance, Epidemiology, and End Results (SEER) Program.

发表日期:2024 Aug 06
作者: Tejas P Joshi, Arash Kimyai-Asadi
来源: CLINICAL AND EXPERIMENTAL DERMATOLOGY

摘要:

数码乳头状腺癌(DPAc)是一种罕见的、侵袭性的汗腺来源的皮肤恶性肿瘤。在此,我们使用监测、流行病学和最终结果 (SEER) 计划的 17 个登记处对 213 名 DPAc 患者进行了回顾性研究。我们估计 DPAc 的发病率为每年每百万人 0.​​11 例,并且在过去二十年中发病率不断上升。我们的研究表明,DPAc 最常困扰白人男性,通常是 40 岁至 60 岁的男性。我们注意到 5 年疾病特异性生存率为 98.3%,5 年总生存率为 95.7%。我们还表明,高龄与更具侵袭性的疾病相关,并将肿瘤大小确定为影响疾病特异性生存的独立危险因素。我们的结果还表明,DPAc 患者随后发生原发性恶性肿瘤的风险较高,男性患肺/支气管肿瘤的风险较高,女性患乳腺癌的风险较高。© 作者 2024 年。已发表由牛津大学出版社代表英国皮肤科医师协会出版。版权所有。如需商业重复使用,请联系 reprints@oup.com 获取转载和转载的翻译权。所有其他权限都可以通过我们网站文章页面上的权限链接通过我们的 RightsLink 服务获得 - 如需了解更多信息,请联系journals.permissions@oup.com。
Digital papillary adenocarcinoma (DPAc) is a rare, aggressive cutaneous malignancy of sweat gland derivation. Herein, we conduct a retrospective study of 213 DPAc patients using the 17 registries of the Surveillance, Epidemiology, and End Results (SEER) program. We estimate the incidence of DPAc to be 0.11 per million persons per year, with the incidence rising over the past two decades. Our study shows DPAc to most commonly afflict White males, typically in their 40s-60s. We note a 5-year disease-specific survival of 98.3% and 5-year overall survival of 95.7%. We also show advanced age to be associated with more aggressive disease and identify tumor size as an independent risk factor impacting disease-specific survival. Our results also suggest that patients with DPAc have an elevated risk of developing subsequent primary malignancies, with males being at increased risk of developing lung/bronchial neoplasms and females being at increased risk of developing breast cancer.© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.